Expert Systems Biology

The BioAnalytics Group LLC

Contact:

Phone: 609-632-0091

Fax: 609-632-1224

E-mail: info@bioanalyticsgroup.com

Cardiac Drug Safety

The Cardiac Model-Based Assay™ simulates millions of laboratory experiments and patient responses,  identifying patient subpopulations that may be at higher risk of adverse reaction.   Our customers consider the information to be valuable in candidate selection and in guiding experiments and clinical trials. 

Collaborating with major pharmaceutical companies and leading academic researchers, The BioAnalytics Group has developed a software platform that analyzes preclinical laboratory data and predicts patient responses, including responses caused by millions of combinations of drug interactions and patient risk factors. Our clients have a more complete understanding of their compounds’ risk profile than ever before.  

Cardiac Arrhythmia

Drug-induced cardiac arrhythmia remains one of the major drug safety issues today.  Health risks include sudden cardiac death, and financial risks to pharmaceutical firms include safety-related drug withdrawals, liability lawsuits, billions of dollars in lost revenue, decimation of candidate portfolios, and adverse publicity.

Many drugs interfere with the normal operation of ion channels that regulate heart rhythm.   Pharmaceutical companies test for the effects for I_kr, the rapidly repolarizing potassium channel, one of the most important ion channels associated with drug-induced arrhythmia.  Today’s drug safety issues, however, are often due to drugs’ effects on multiple ion channels,  or drug interactions that effect multiple ion channels. Pharmaceutical firms evaluate the consequences of mixed ion channel effects by testing the drugs on animals and humans, as recommended by the FDA.

Preclinical testing and clinical trials produce drugs that are safe for most people, but rare combinations of drug dose, drug interactions and patient risk factors can result in adverse cardiac drug reactions.   Patient risk factors known to be involved in drug-induced arrhythmia include sex, diet, health history and numerous genetic risk factors.   It is simply infeasible to conduct enough laboratory or clinical tests to evaluate all combinations of drug interactions and risk factors, so adverse reactions are not identified until drugs reach the market.

Contact us to find out how you can be better informed about your compound’s potential proarrhythmic risk.

Know more about your compound’s safety risk before going to market, using our Cardiac Model-Based Assay^tm system.